Protective effect of coenzyme Q10 in cyclophosphamide-induced kidney damage in rats

Kara, Ozlem

doi:10.1590/1806-9282.20230990

Acessibilidade / Reportar erro

Brasil

Revista da Associação Médica Brasileira

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Article • Rev. Assoc. Med. Bras. 70 (4) • 2024 • https://doi.org/10.1590/1806-9282.20230990 copy

Protective effect of coenzyme Q10 in cyclophosphamide-induced kidney damage in rats

Authorship SCIMAGO INSTITUTIONS RANKINGS

SUMMARY

OBJECTIVE:

We aimed to investigate the effect of coenzyme q10 on cyclophosphamide-induced kidney damage in rats.

METHODS:

A total of 30 female Wistar-Albino rats were utilized to form three groups. In group 1 (control group) (n=10), no drugs were given. In group 2 (cyclophosphamide group) (n=10), 30 mg/kg intraperitoneal cyclophosphamide was administered for 7 days. In group 3 (cyclophosphamide+coenzyme q10 group) (n=10), 30 mg/kg cyclophosphamide and 10 mg/kg coenzyme q10 were given for 7 days via intraperitoneal route. Right kidneys were removed in all groups. Blood malondialdehyde levels and activities of catalase and superoxide dismutase were measured. Histopathological damage was evaluated by examining the slides prepared from kidney tissue using a light microscope.

RESULTS:

Tissue damage was significantly higher in the cyclophosphamide group than in the cyclophosphamide+coenzyme q10 group (p<0.05). The malondialdehyde levels were significantly higher and the activities of superoxide dismutase and catalase were lower in the cyclophosphamide group than in the cyclophosphamide+coenzyme q10 group (p<0.05).

CONCLUSION:

Coenzyme q10 may be a good option to prevent cyclophosphamide-induced kidney damage.

KEYWORDS:
Cyclophosphamide; Coenzyme q10; Rat; Kidney; Toxicity

	MDA (nmol/mg)	SOD (U/mg)	CAT (U/mg)
(Control group) (n=10)	16.59±7.08	29.4±10.81	69.58±17.72
(Cyclophosphamide group) (n=10)	35.12±13.85^* * Significant difference (p<0.05) between groups 2 and 3. Data are presented as mean±SD.	11.27±3.14^* * Significant difference (p<0.05) between groups 2 and 3. Data are presented as mean±SD.	27.56±10.41^* * Significant difference (p<0.05) between groups 2 and 3. Data are presented as mean±SD.
(Cyclophosphamide+coenzyme q10 group) (n=10)	23.66±10.27^* * Significant difference (p<0.05) between groups 2 and 3. Data are presented as mean±SD.	19.31±8.76^* * Significant difference (p<0.05) between groups 2 and 3. Data are presented as mean±SD.	40.67±16.70^* * Significant difference (p<0.05) between groups 2 and 3. Data are presented as mean±SD.

	(Cyclophosphamide group) (n=10)	(Cyclophosphamide+coenzyme q10 group) (n=10)
Hemorrhage	2.00^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.	1.00^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.
Necrosis	1.00	1.00
Edema	2.00^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.	1.00^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.
Inflammation	2.00^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.	1.00^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.
Tubular dilatation	2.76^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.	1.56^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.
Glomerular atrophy	2.37^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.	1.03^* * Significant difference (p<0.05) between groups 2 and 3. Histopathological scoring was done by determining the highest area. Four categories (0: None, 1: Minimal, 2: Mild, 3: Moderate, and 4: Severe) were determined by making a semi-quantitative analysis, and the parameters were scored accordingly.

Associação Médica Brasileira R. São Carlos do Pinhal, 324, 01333-903 São Paulo SP - Brazil, Tel: +55 11 3178-6800, Fax: +55 11 3178-6816 - São Paulo - SP - Brazil
E-mail: ramb@amb.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] *Corresponding author: ozlemozturk34@hotmail.com